Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab

BACKGROUND: The occurrence of acute promyelocytic leukemia (APL) during the management of lung cancer is rare and life-threatening. It was mainly reported to be secondary to chemoradiotherapy. A few studies reported an increased incidence of therapy-related acute promyelocytic leukemia (t-APL) after...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Huohuan, Yang, Linhui, Hou, Wang, Wu, Yu, Dai, Yang, Yu, Jiang, Liu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880289/
https://www.ncbi.nlm.nih.gov/pubmed/36713543
http://dx.doi.org/10.3389/fonc.2022.1032225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880289/
https://www.ncbi.nlm.nih.gov/pubmed/36713543
http://dx.doi.org/10.3389/fonc.2022.1032225

Ejemplares similares